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A B S T R A C T
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:
To assess the effects of transcranial direct current stimulation (tDCS) on fatigue, motor function, and pain in people with MS.
B A C K G R O U N D
Description of the condition
Multiple sclerosis (MS) is a chronic autoimmune, inflamma-
tory, and neurodegenerative disease of the central nervous sys-
tem (CNS) with global prevalence rates estimated at 2.3 million
(Browne 2014; MSIF 2013). The prevalence of MS is known to
follow a geographical gradient, with higher prevalence rates in ar-
eas that are farther from the equator such as North America and
Europe (140 and 108 per 100,000 respectively) and lower preva-
lence rates in areas that are closer to the equator such as sub-Sa-
haran Africa (2.1 per 100,000) (MSIF 2013). Multiple sclerosis is
known to have a varied disease course, and traditional clinical mod-
els have categorised MS phenotypes as relapsing-remitting MS
(RRMS), primary-progressive MS (PPMS), secondary-progressive
MS (SPMS), and progressive-relapsing MS (PRMS). However, re-
cent recommendations call for improved clinical and radiologi-
cal descriptors to better characterise currently existing phenotypes
(Lublin 2014). In addition, clinically isolated syndrome (CIS) has
been proposed as a phenotype in the MS spectrum (Lublin 2014).
Individuals with MS are known to present with a wide array of
neurological symptoms that may occur in isolation as sudden at-
tacks, or in combination, arising from different areas of the CNS
(Milo 2014). Classical signs and symptoms include sensory loss,
motor symptoms, such as muscle weakness and/or spasticity, auto-
nomic symptoms such as bowel, bladder, and sexual dysfunction,
and deficits in co-ordination and balance, vision, and cognition
(Milo 2014). Fatigue is another frequently reported symptom that
is known to affect approximately 50% to 80% of adults with MS
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(Krupp 2010; Lerdal 2007). Fatigue is more frequently reported
in people with PPMS and SPMS compared to RRMS (Leocani
2008; Patrick 2009). Although the pathophysiology of fatigue is
not completely understood, experts believe that fatigue in MS may
have a central origin, and studies have reported an impairment
in the corticomotor drive to the descending motor system as a
causative mechanism (Leocani 2008; Patrick 2009). Fatigue ap-
pears to be at its worst in the afternoon (Krupp 2010; Leocani
2008), and is known to increase in hot or humid environments
(Bakshi 2003). Over the course of the disease, individuals with
MS experience significant functional disability that can severely
affect their quality of life and eventually increase caregiver burden
(Lobentanz 2004). In particular, deficits in walking can be particu-
larly frustrating for those with MS and their caregivers. Individuals
with MS can have limitations in day-to-day mobility due to mus-
cle weakness, spasticity, sensory loss, and problems with balance.
In addition, cognitive deficits can worsen walking and increase risk
of fall. Spasticity is highly prevalent in MS and can impede func-
tional activities such as transfers and ambulation, thus increasing
disability (Barnes 2003). Moreover, spasticity is correlated with
pain, and therefore has an impact on patients’ quality of life. Even-
tually, decrease in mobility can further increase the severity of MS-
related symptoms (e.g. a decrease in activity and sustaining one
position for a long time can increase fatigue and pain and cause
other comorbidities such as respiratory- and urinary tract-related
complications). In addition to functional dysfunction, individu-
als with MS may suffer from pain. Pain prevalence reports in MS
are variable; a recent study reported that around 63% of adults
with MS manifest with pain at some point during their disease
(Foley 2013). Multiple sclerosis is characterised by different pain
syndromes such as headache, neuropathic pain, Lhermitte’s phe-
nomenon, painful tonic spasms, musculoskeletal pain, trigeminal
neuralgia, and others (Foley 2013; Truini 2013). Given that indi-
viduals with MS can present with various combinations of these
symptoms, current research is seeking to explore the efficacy of
different rehabilitation approaches.
Description of the intervention
Transcranial direct current stimulation (tDCS) is a non-invasive
neuromodulatory tool that can potentially improve motor func-
tion in several neurological disorders such as stroke, spinal cord
injury, Parkinson’s disease, and others (Fregni 2005; Fregni 2006;
Gandiga 2006; Hummel 2005). Low intensity direct currents are
delivered through electrodes on the scalp that can modulate corti-
cal excitability (Nitsche 2000) and produce behavioural changes to
promote functional performance (Giordano 2017; Roche 2015).
The dosage typically includes a current intensity of 1 to 2 mA
delivered for 5 to 20 minutes with electrodes sizes ranging from
25 to 35 cm2 (Nitsche 2008). Stimulation related after-effects are
dependent on stimulation polarity and duration, current inten-
sity, and electrode size. tDCS is a safe technique and usually elicits
a mild itching sensation that fades after a few seconds of stimu-
lation (Nitsche 2000). tDCS protocols can be controlled with a
sham condition, also known as placebo tDCS. Sham stimulation
includes the ramp up and ramp down of current (producing initial
tingling sensations to mimic the active stimulation), but the cur-
rent is delivered for a very short period of time (e.g. 30 seconds) .
How the intervention might work
Transcranial direct current stimulation can modulate corticomotor
excitability by inducing bidirectional polarity specific effects. An-
odal tDCS (where the anode (+) is placed over the target area) in-
creases cortical excitability, and cathodal tDCS (cathode (-) placed
over the target area) decreases cortical excitability (Nitsche 2000).
tDCS modulates neuronal membrane potentials that affect neu-
ronal excitability and the resulting effects can last longer than the
stimulation period (Stagg 2011). Studies have also shown that
tDCS-related after effects may depend on glutamatergic mecha-
nisms resulting in possible induction of long-term potentiation
(LTP)-like effects that can promote neuronal plasticity (Nitsche
2000; Nitsche 2001; Pelletier 2014). Several studies have inves-
tigated the effects of tDCS on the primary motor cortex of the
hand muscle representations. More often, researchers use proto-
cols incorporating anodal tDCS to enhance motor function. An-
odal stimulation when combined with a motor or cognitive task
can render the brain’s circuits more responsive to the accompany-
ing task, thus increasing the effectiveness of tDCS (Fregni 2005a;
Reis 2009). Recent studies suggest that in individuals with MS,
anodal tDCS over the motor cortex or prefrontal area may re-
duce pain and improve fatigue severity as compared with sham
tDCS (Ayache 2016; Ayache 2017; Ferrucci 2014; Mori 2010).
Although research in tDCS is gaining momentum, optimal dosage
parameters for stimulation such as current intensity, duration, and
electrode size have yet to be identified.
Why it is important to do this review
The higher rates of prevalence of fatigue, movement disability,
and pain in MS warrant an evidence-based approach to develop
appropriate treatment modalities for people with MS. All these
symptoms significantly impact individuals’ quality of life, and even
though tDCS is being explored as an intervention (Ferrucci 2014;
Mori 2010), issues such as interindividual variability warrant a
need for adequate synthesis of information regarding its efficacy.
Although some studies report that tDCS may be effective in MS,
it is unclear which target area of the brain (motor cortex versus
other areas) may be optimal sites for stimulation. Currently, no
systematic review has evaluated the effectiveness of tDCS in MS.
Factors such as cost-effectiveness, ease of application, and porta-
bility of tDCS devices increase its potential as a clinical adjunct
to other therapies. It is therefore important to comprehensively
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synthesise the current literature to establish the clinical utility of
tDCS for improving fatigue, motor function, and pain in people
with MS.
O B J E C T I V E S
To assess the effects of transcranial direct current stimulation
(tDCS) on fatigue, motor function, and pain in people with MS.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We will include randomized controlled trials with cross-over and
parallel-group designs. We will also include quasi-randomized tri-
als.
Types of participants
We will include adults, males and females (18 years or older)
with clinically definite MS according to the McDonald criteria
and its revisions and all subgroups of MS such as relapsing-remit-
ting, primary-progressive, progressive-relapsing, and secondary-
progressive (Polman 2005; Polman 2011; Poser 1983; Thompson
2018). We will exclude individuals with other neurological and
non-neurological comorbidities that may affect motor function,
pain, and fatigue.
Types of interventions
We will include all trials that evaluate tDCS in people with MS,
regardless of unilateral or bilateral stimulation, anodal or cathodal
stimulation, dosage, intensity, duration, electrode size, or cortical
targets for stimulation. We will include as control interventions
sham treatment or no treatment or conventional treatment. Ac-
ceptable conventional treatments will include interventions such
as rehabilitation or exercise therapy or other training (such as yoga,
tai-chi, etc.) or other therapies to improve motor function, fatigue,
or pain.
We will investigate the following comparisons.
• tDCS only compared with sham tDCS
• tDCS and conventional therapy (for improving motor
function, pain, and fatigue) compared with sham tDCS and
conventional therapy
• tDCS and conventional therapy compared with
conventional therapy alone
• tDCS only compared with no treatment
Types of outcome measures
We will examine outcomes that are measured pre- and postinter-
vention and at the end of follow-up (e.g. six months or one year
or other follow-up periods).
Primary outcomes
Fatigue measured using:
◦ Fatigue Impact Scale (FIS) (Fisk 1994);
◦ Modified Fatigue Impact Scale (MFIS) (Fisk 1994);
◦ Fatigue Severity Scale (FSS) (Krupp 1989);
◦ Multidimensional Fatigue Inventory (MFI) (Smets
1995);
◦ visual analogue scale (VAS);
◦ Patient-Reported Outcomes Measurement
Information System (PROMIS) (Cella 2010).
Motor function measured using:
◦ muscle strength (Medical Research Council Scale);
(Compston 2010)
◦ grip strength (measured by a dynamometer);
◦ pinch force (measured by a dynamometer or similar
device).
• Upper limb motor function measured using:
◦ Action Research Arm Test (ARAT) (Lyle 1981);
◦ Nine-Hole Peg Test (NHPT) (Mathiowetz 1985).
• Lower limb motor function and mobility measured using:
◦ Functional Ambulation Categories (FAC) (Holden
1984);
◦ Timed Up and Go test (TUG) (Podsiadlo 1991);
◦ MS-Walking Scale 12 (Hobart 2003);
◦ 6-minute walk test (6 MWT) (Enright 2003).
Pain measured using:
◦ VAS;
◦ numerical rating scales (NRS) (Farrar 2001);
◦ McGill Pain Questionnaire (MPQ) (Melzack 1975);
◦ Short Form McGill Questionnaire (SF-MPQ)
(Melzack 1987);
◦ Brief Pain Inventory-short form (BPI-sf ) (Mendoza
2006).
Spasticity measured using:
◦ Ashworth Scale (AS); (Pandyan 1999)
◦ Modified Ashworth Scale (MAS) (Bohannon 1987);
◦ Composite Spasticity Scale (CSS);
◦ Multiple Sclerosis Spasticity Scale (MSSS-88) (Hobart
2006).
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Adverse events - We will monitor the incidence (i.e. number)
of tDCS related adverse events (AEs) and serious adverse events
(SAEs). If enough studies do not report the total number of AEs,
SAEs, and person-years, we will use the number of participants
with at least one AE or SAE as defined in the study.
Adverse events of tDCS will include minor symptoms such as tran-
sient itching, burning, tingling, headache, scalp discomfort, pain,
nausea, contact dermatitis, skin redness, fatigue and other sensa-
tions. Serious adverse events will include seizures and psychotic
symptoms such as mood changes, irritability and all other serious
adverse events reported in the included studies.
Secondary outcomes
• Quality of life measured using such tools as the 36-Item
Short Form Health Survey (SF-36) (Ware 1992), 12-Item Short
Form Health Survey (SF-12), and Multiple Sclerosis Quality of
Life-54 (MSQoL-54) (Vickrey 1995).
• Depression measured using such tools as Beck’s Depression
Inventory (BDI) and Hamilton Depression Rating Scale
(HDRS) (Beck 1996; Williams 1988).
• MS progression measured with the Kurtzke Expanded
Disability Status Scale (EDSS) (Kurtzke 1983).
• Tactile perception measured using such tools as grating
orientation task (GOT) and VAS (Craig 1999).
• Cognition measured using such tools as Symbol Digit
Modalities Test (SDMT) (Smith 1982), Wisconsin Card Sorting
Test (WCST) (Heaton 1981), Paced Auditory Serial Addition
Test (PASAT) (Gronwall 1977), and Attention Network Test
(ANT) (Macleod 2010).
Search methods for identification of studies
Electronic searches
The Information Specialist will search the Cochrane Multiple Scle-
rosis and Rare Diseases of the Central Nervous System Group
Trials Register, which contains trials from the following sources,
among others.
• The Cochrane Central Register of Controlled Trials
(CENTRAL) (latest issue).
• MEDLINE (PubMed) (1966 to date).
• Embase (1974 to date).
• CINAHL (EBSCO host) (Cumulative Index to Nursing
and Allied Health Literature) (1981 to date).
• LILACS (BIREME) (Latin American and Caribbean
Health Science Information database) (1982 to date).
• PEDro (Physiotherapy Evidence Database) (1990 to date).
• ClinicalTrials.gov (www.clinicaltrials.gov).
• World Health Organization ( WHO) International Clinical
Trials Registry Platform ( ICTRP) ( apps.who.int/trialsearch).
Information on the Group’s Trials Register and details of search
strategies used to identify trials can be found in the ’Specialised
Register’ section within the Cochrane Multiple Sclerosis and Rare
Diseases of the Central Nervous System Group’s module. The
keywords used to search for trials for this review are listed in
Appendix 1.
Searching other resources
In addition we will:
• screen the reference lists of review articles and primary trials
on this topic;
• screen the following relevant conference proceedings:
World Congress of NeuroRehabilitation, American Congress of
Rehabilitation Medicine, American Society of
NeuroRehabilitation and Brain Stimulation;
• contact experts in the field for additional data and to
identify further published or unpublished trials;
• contact principal authors of abstracts or unpublished
manuscripts for sharing of their unpublished data.
Data collection and analysis
Selection of studies
Three review authors (AS, AH, and AT) will independently screen
and select trials based on the inclusion criteria of the review. We
will screen the titles and abstracts for all the citations. Next, we
will obtain the full text of the selected citations, and based on their
eligibility, select articles for inclusion. Any disagreements regarding
inclusion will be resolved by mutual discussion or by referral to a
fourth review author (FF) when necessary.
Data extraction and management
For each included study, two review authors (AS, AH) will inde-
pendently extract data from the selected trials using data extrac-
tion forms, and enter the data into Review Manager 5 (Review
Manager 2014). We will extract data based on the following:
• study characteristics (study design, inclusion and exclusion
criteria);
• characteristics of participants (number, age, gender, type of
MS, time from symptom onset to diagnosis);
• type and length of experimental intervention (stimulation
site, parameters and dosage);
• type and length of control intervention;
• methodological quality of studies;
• description of outcomes.
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Assessment of risk of bias in included studies
We will assess risk of bias using the Cochrane ’Risk of bias’ assess-
ment tool as outlined in the Cochrane Handbook for Systematic Re-
views of Interventions (Higgins 2011a). For parallel-group designs,
we will assess the following ’Risk of bias’ domains: sequence gen-
eration, allocation concealment; blinding of participants and per-
sonnel; blinding of assessors; incomplete outcome data; selective
reporting; and whether free of other bias. For cross-over study de-
signs, we will assess the aforementioned domains as well as whether
the data are free from carry-over effects. We will judge each do-
main as at low, high, or unclear risk of bias (we will assess a do-
main as unclear when information is insufficient to make a judge-
ment of ’low’ or ’high’ and study authors do not respond to our
queries when contacted). We will provide a quote from the study
and justification for the judgement for each domain in the ’Risk
of bias’ table. We will assess risk of bias for all outcomes within a
study. Overall risk of bias for each study will be judged at ’low risk
of bias’ when all three domains (allocation concealment, blinding
of outcome assessment and incomplete outcome assessment) are
assessed at ’low risk of bias’; ’high risk of bias’ when at least one
domain is assessed at ’high risk of bias’; and ’unclear risk of bias’
in the remaining cases.
Two review authors (AS and AH) will independently assess risk of
bias for each study. Any disagreements between the authors on the
methodological quality of the identified studies will be resolved
by referral to a third reviewer (AT). We will contact the authors of
the included studies for any additional information on the study
methods.
GRADE assessment and ’Summary of findings’ table
We will provide the main findings of the review in ’Summary
of findings’ tables using GRADEpro GDT software (GRADEpro
GDT 2015). The tables will include a list of all primary outcomes
(fatigue, motor function, pain, spasticity and adverse events), mag-
nitude of effect of the intervention, number of participants, and
overall certainly of evidence for each outcome. For each primary
outcome, we will assess the certainty of the evidence using the
GRADE approach (Balshem 2010), which is based on consider-
ation of risk of bias, inconsistency, indirectness, imprecision, and
publication bias. We will assess the certainty of the evidence for
each outcome as high, moderate, low, or very low.
Measures of treatment effect
Continuous data
For all continuous outcomes, we will compute the mean difference
(MD) with 95% CI as a measure of treatment effect if the out-
comes are measured in the same way among trials. If some studies
report endpoint data, and others report change from baseline data,
we will combine these studies in a meta-analysis if the outcomes
have been reported using the same scale. We will compute the
standardised mean difference (SMD) with 95% CI to combine
trials that measure the same outcome using different scales. For
every study, we will compute MD or SMD and the corresponding
95% CI. If the studies do not report mean and standard deviation
(in case the data is skewed), we will use the method as proposed
by the author to calculate mean and variance from median, range,
and sample size (Hozo 2005). If the range is not mentioned in the
article, we will contact the authors for this information.
Ordinal data
We will use the methods described in the Cochrane Handbook for
Systematic Reviews of Interventions to analyse ordinal and measure-
ment scale outcomes. We will consider the ordinal outcome as
continuous if it has many categories (preferably more than four),
or we will compute the proportional odds ratio and pool the data
using the generic inverse-variance method (Deeks 2011). We will
compute the proportional odds ratio using Stata 13.1 (Stata 2013).
We will use risk ratio (RR) and 95% CI for AEs and SAEs.
Unit of analysis issues
Studies with more than two treatment groups
If we identify studies with two or more intervention groups (multi-
arm studies), we will combine all intervention arms into a single
intervention group (e.g. intervention arms with multiple tDCS
dosages will be combined), and we will combine all relevant con-
trol groups into a single control group (e.g. sham tDCS, no treat-
ment and/or conventional treatments will be combined) (Higgins
2011b). We will follow the method suggested in Table 7.7.a in the
Cochrane Handbook for Systematic Reviews of Interventions (Higgins
2011c). While performing subgroup analysis, if the interventions
belong to a different subgroup, we will consider that as a separate
study. Additionally, we will divide the control group (events and
total population) with the number of relevant subgroups to avoid
double-counting of participants.
Cross-over trials
We will consider data only from the first period of measurement
in the meta-analysis, or if possible we will perform an appropriate
paired analysis (Higgins 2011b). If the studies do not provide a
within-participant correlation coefficient, we will impute the value
for a correlation coefficient from another study in the meta-analysis
as per the Cochrane Handbook for Systematic Reviews of Interventions
(Higgins 2011b). We will also conduct a sensitivity analysis for
different values of within-participant correlation coefficient.
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Dealing with missing data
We will contact the authors if outcome data are unclear or have not
been completely reported. We will capture the missing information
in the data extraction form and report it in the ’Risk of bias’ tables.
For all outcomes, we will perform an intention-to-treat analysis
and attempt to include all participants randomised to each group.
Assessment of heterogeneity
We will use a random-effects model, regardless of the level of
heterogeneity. We will use the I2 statistic to assess heterogeneity,
considering an I2 greater than 50% as substantial heterogeneity.
Assessment of reporting biases
If we identify at least 10 trials reporting the same outcome of inter-
est, we will assess publication bias using funnel plots. Otherwise,
we will use Egger’s test for assessing reporting bias (Sterne 2011).
Data synthesis
We will analyse the data using Review Manager 5 (Review Manager
2014). We will perform a meta-analysis to provide an overall es-
timate of the treatment effect when data from more than one
study using the same comparison are available. We will adopt a
random-effects model for meta-analysis in anticipation of natural
heterogeneity between studies that may be due to different tDCS
target areas, dosages, intensities, durations, types of stimulation,
electrode sizes, length of interventions, and types of MS. For con-
tinuous variables, we will use the inverse-variance method. If we
are unable to perform a meta-analysis due to substantial differ-
ences between studies, we will perform a narrative synthesis of the
data. We will not combine results from randomised and quasi-
randomised trials together in the meta-analysis.
Subgroup analysis and investigation of heterogeneity
If we identify three or more studies, we will undertake subgroup
analyses to explore potential sources of heterogeneity based on the
following.
• Type of MS: RRMS, PPMS, SPMS, and PRMS
• Type of stimulation: cathodal versus anodal stimulation
• Target area of stimulation: dorsolateral prefrontal cortex,
motor cortex and other areas
• Dosage of stimulation: current intensity, electrode size and
duration of stimulation
• Length of intervention: single session versus multiple
sessions
• Electrode size
All subgroup analyses will be accompanied by appropriate tests
for interaction, that is statistical tests for subgroup differences as
described in the Cochrane Handbook for Systematic Reviews of In-
terventions (Higgins 2011), and implemented in Review Manager
5 (Review Manager 2014).
Sensitivity analysis
We will perform a sensitivity analysis to examine the robustness
of the estimates by removing studies at high risk of bias from the
meta-analysis. If we include cross-over trials in the review, we will
perform a sensitivity analysis for different values of the within-
participant correlation coefficient.
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Appendix 1. Keywords
1 Electric Stimulation Therapy/
2 Electric Stimulation/
3 Electrodes/
4 (transcranial adj5 direct current adj5 stimulation).tw.
5 (transcranial adj5 DC adj5 stimulation).tw.
6 (transcranial adj5 electric$ adj5 stimulation).tw.
7 (tDCS or A-tDCS or C-tDCS or S-tDCS or electrode$ or anode or anodes or anodal or cathode or cathodes or cathodal).tw
8 or/1-8
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